Rivaroxaban post-TAVR ups thromboembolic risk in GALILEO
28 Nov 2019
byRoshini Claire Anthony
Rivaroxaban treatment after successful transcatheter aortic valve replacement (TAVR) for aortic valve stenosis is linked to an increased risk of death, thromboembolic events, and bleeding in patients without an indication for oral anticoagulation, results of the GALILEO* trial showed.